IPO Corner: Corona Remedies Ltd.

Corona Remedies Limited will open the Bid / Offer in relation to its initial public offering (IPO) of the Equity Shares on Monday, December 08, 2025. The Bid/Offer will close on Wednesday, December 10, 2025. The Price Band has been fixed at ₹1,008 to ₹1,062 per Equity Share.

• Issue Opens: December 8, 2025
• Issue Closes: December 10, 2025
• Face Value: Rs 10 each
• Price Band: Rs 1008 – 1062 per share
• Lot Size: 14 Shares
• Issue Type: Book Built Issue
  Total Fresh Issue Size: Up to 16,80,000 Shares
  Listing: BSE & NSE

The Anchor Investor Bidding Date shall be on Friday, December 05, 2025. Bids can be made for a minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter. A discount of ₹ 54 per Equity Share is being offered to Eligible Employees bidding in the Employee Reservation Portion.

The Equity Shares, offered through the Red Herring Prospectus of the Company are proposed to be listed on National Stock Exchange of India Limited and BSE Limited.

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. The company has a diversified product portfolio comprising 71 brands catering to a range of therapeutic areas as of June 30, 2025.

According to the CRISIL Intelligence Report, Corona Remedies is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (“IPM”) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. *MAT is the moving annual total. Corona Remedies was the second fastest growing company among the top 30 companies in the IPM in terms of domestic sales between MAT June 2022 and MAT June 2025.

• Women’s healthcare: Brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories;

• Cardio-diabeto: Brands across different stages of diabetes treatment, ranging from insulin resistance, pre-diabetes to diabetes and diabetes-related complications, as well as cardiac disorders such as hypertension, dyslipidemia and ischemic heart disease;

• Pain Management: Four dosage forms in pain management formulations, which the company offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes neuropathy pain, among others.

• Urology: Brand offerings across multiple urological disorders, such as benign prostatic hyperplasia, overactive bladder, urinary tract infections and stone management.